TDC
ESPR

Thompson Davis & Co’s Esperion Therapeutics ESPR Stock Holding History

Thompson Davis & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-125
Closed -$2K – 1139
2016
Q3 		$2K Buy
+125
New +$1.42K ﹤0.01% 994
2016
Q2 		– Sell
-250
Closed -$4K – 1095
2016
Q1 		$4K Buy
+250
New +$4.02K 0.01% 830

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Thompson Davis & Co's ESPR Position: Q4 2016 in Review

Thompson Davis & Co sold out of Esperion Therapeutics (ESPR) in Q4 2016, closing a stake of 125 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in ESPR in Q1 2016 and held it in 2 quarters. The position peaked at $4K in Q1 2016. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

  • Thompson Davis & Co reported no remaining Esperion Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Esperion Therapeutics shares in Q4 2016, an estimated $2K.
  • Thompson Davis & Co first reported a position in Esperion Therapeutics in Q1 2016 and held it in 2 quarters.
  • Thompson Davis & Co's Esperion Therapeutics position peaked at $4K in Q1 2016.
  • 99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.